跳至主要内容
临床试验/DRKS00026630
DRKS00026630招募中未知

Dietary Intervention with Maritime Pine Bark Extract Pycnogenol® to Reveal the Course of Bone Loss in Osteopenia and clinically stable Osteoporosis - PROtectO

Klinische StudieneinheitOrthopädische Klinik, Universität Würzburg0 个研究点目标入组 76 人开始时间: 2021年9月14日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
76

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
All

入选标准

  • Males / females, age = 18 years
  • - Increased 10-year fracture risk =20 % according to the National German Guidelines for Diagnosis and
  • Treatment of Osteoporosis for postmenopausal women and men = 60 years of age
  • - DXA T-Score = -1,0 at either total hip, femoral neck or lumbar spine
  • - Signed informed consent

排除标准

  • - Current / ongoing treatment with bisphosphonates, denosumab, strontium ranelate, teriparatide,
  • odanacatib or romosozumab
  • - Osteoporotic fracture within 3 months prior to enrollment
  • - Given medical indication for treatment with bisphosphonates, denosumab, strontium ranelate, teriparatide,
  • odanacatib or romosozumab according to applicable national guidelines with the following
  • exceptions:
  • * Participant refuses to take such medication
  • * Participant cannot be treated due to contraindications or an unfavorable risk/benefit ratio
  • * Participant was previously treated with such medication and is now pausing is considered to
  • avoid long-term treatment associated side-effects
  • - Use of nutritional supplements

研究者

发起方
Klinische StudieneinheitOrthopädische Klinik, Universität Würzburg

相似试验